Form 4: Cytosorbents CEO Phillip Chan Acquires Stock Options Through Salary Reduction
SEC Form 4 Filing
Cytosorbents CEO Phillip P. Chan acquired 129,998 stock options on March 29, 2024, as part of a voluntary salary reduction program.
Summary
- Phillip P. Chan, CEO of Cytosorbents Corp, acquired 129,998 stock options on March 29, 2024.
- The options were granted as part of a voluntary salary reduction program for the period from April 1, 2024, to December 31, 2024.
- The exercise price of the stock options is $0.95.
- The stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan.
- The shares underlying the stock options will vest fully on January 31, 2025, subject to continued service.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The CEO taking a salary reduction to receive stock options can be seen as a positive sign of commitment, but it's a routine transaction.
Positives
- The CEO's participation in a voluntary salary reduction program demonstrates commitment to the company.
- The granting of stock options aligns the CEO's interests with those of the shareholders.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting date of the stock options.
Industry Context
This filing is a routine disclosure of insider transactions, common in publicly traded companies. It reflects executive compensation practices and alignment of management interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation packages.
- The vesting schedule and exercise price are typical for such grants, aligning with industry norms for long-term incentive plans.
Stakeholder Impact
- Shareholders may view the CEO's participation in the salary reduction program and subsequent stock option grant as a positive sign of alignment with their interests.
- Employees may see this as a sign of the CEO's commitment to the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 03/29/2024 | Date of the transaction where stock options were acquired. |
| 04/01/2024 | Start date of the voluntary salary reduction period. |
| 12/31/2024 | End date of the voluntary salary reduction period. |
| 01/31/2025 | Date when the shares underlying the stock options will fully vest. |
| 03/29/2034 | Expiration date of the stock options. |
| 04/02/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.